A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Notify the Multiple Myeloma Research Foundation you are interested in this trial

NCT06066346

Age 18 +

Sex Both

Phase Phase 2

Third Opinion Trial Synopsis

In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and potentially offer a more effective treatment option. Here are some key details about the study:

The study investigates a unique combination of therapies that have not been widely used together before.
It aims to assess how well this combination works in treating patients with the disease.
Participants will receive the treatment in a controlled environment, allowing researchers to closely monitor their progress and any side effects.
The study includes various assessments to evaluate the effectiveness of the treatment, including blood tests and imaging studies.
Researchers are particularly interested in how this treatment can improve patients' quality of life and overall health outcomes.

This study is significant because it may lead to new treatment options that could be more effective than current therapies, providing hope for patients seeking better management of their condition.

Third Opinion AI Generated Synopsis

Trial Summary
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:

Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: